Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation

  • Park, Shin-Hyung (Department of Radiation Oncology, School of Medicine, Kyungpook National University) ;
  • Kim, Jae-Chul (Department of Radiation Oncology, School of Medicine, Kyungpook National University)
  • Received : 2019.12.25
  • Accepted : 2020.03.03
  • Published : 2020.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the necessity of regional nodal irradiation (RNI) for pT1-2N1 breast cancer patients treated with breast-conserving surgery and radiotherapy, we compared clinical outcomes of patients treated with and without RNI. Materials and Methods: We retrospectively analyzed the data of 214 pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation from 2007-2016. There were 142 (66.4%), 51 (23.85%), and 21 (9.8%) patients with one, two, and three positive lymph nodes, respectively. Thirty-six patients (16.8%) underwent RNI. Adjuvant chemotherapy, endocrine therapy, and anti-HER2 therapy were given to 91.6%, 79.0%, and 15.0% patients, respectively. The most common chemotherapy regimen was anthracycline + cyclophosphamide, followed by taxane (76.5%). The median follow-up was 64 months (range, 6 to 147 months). Patients were propensity matched 1:2 into RNI and no-RNI groups. Results: Two patients experienced locoregional recurrences simultaneously with distant metastases, ten patients developed distant metastases, and one patient died. Before matching, the 5-year actuarial locoregional control (LRC), distant metastasis-free survival (DMFS), and overall survival (OS) rates in the RNI and no-RNI groups were 100.0% and 99.4% (p = 0.629), 94.1% and 96.0% (p = 0.676), and 100.0% and 99.4% (p = 0.658), respectively. After matching, the 5-year LRC, DMFS, and OS were 98.3% and 100.0% (p = 0.455), 96.6% and 93.9% (p = 0.557), and 100.0% and 100.0% (p > 0.999) in the RNI and no-RNI groups, respectively. No clinicopathologic or treatment-related factors were significantly associated with LRC, DMFS, or OS. Conclusion: Adding RNI did not show superior LRC, DMFS, or OS in pT1-2N1 breast cancer patients.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
  2. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51:417-30. https://doi.org/10.4143/crt.2019.138
  3. Yoshimura A, Ito H, Nishino Y, et al. Recent improvement in the long-term survival of breast cancer patients by age and stage in Japan. J Epidemiol 2018;28:420-7. https://doi.org/10.2188/jea.JE20170103
  4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44. https://doi.org/10.1016/S0140-6736(11)61625-5
  5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  6. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 1996;88:1659-64. https://doi.org/10.1093/jnci/88.22.1659
  7. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41. https://doi.org/10.1056/NEJMoa022152
  8. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20:4141-9. https://doi.org/10.1200/JCO.2002.11.101
  9. Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001;12:997-1003. https://doi.org/10.1023/A:1011136326943
  10. Winzer KJ, Sauer R, Sauerbrei W, et al. Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2004;40:998-1005. https://doi.org/10.1016/j.ejca.2004.01.007
  11. National Comprehensive Cancer Network. NCCT Guidelines: breast cancer (Version 1.2018) [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network; c2019 [cited 2020 Mar 1]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
  12. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015 373:307-16. https://doi.org/10.1056/NEJMoa1415340
  13. Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015;373:317-27. https://doi.org/10.1056/NEJMoa1415369
  14. Reisenbichler ES, Lester SC, Richardson AL, Dillon DA, Ly A, Brock JE. Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am J Clin Pathol 2013;140:487-94. https://doi.org/10.1309/AJCP1RF9FUIZRDPI
  15. Rakha EA, Starczynski J, Lee AH, Ellis IO. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology 2014;64:609-15. https://doi.org/10.1111/his.12357
  16. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-47. https://doi.org/10.1093/annonc/mdr304
  17. Yu JI, Park W, Huh SJ, et al. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer. Int J Radiat Oncol Biol Phys 2010;78:1135-41. https://doi.org/10.1016/j.ijrobp.2009.09.037
  18. Kim J, Kim JH, Kim OB, Oh YK, Park SG. Clinical significance of the lymph node ratio in N1 breast cancer. Radiat Oncol J 2017;35:227-32. https://doi.org/10.3857/roj.2017.00101
  19. Viani GA, Godoi da Silva LB, Viana BS. Patients with N1 breast cancer: who could benefit from supraclavicular fossa radiotherapy? Breast 2014;23:749-53. https://doi.org/10.1016/j.breast.2014.08.001
  20. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42:1-28.
  21. Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal 2007;15(3):199-236. https://doi.org/10.1093/pan/mpl013
  22. The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology 2016;49(4):170-84.
  23. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 B&C randomized trials. Radiother Oncol 2007;82:247-53. https://doi.org/10.1016/j.radonc.2007.02.001
  24. Kim H, Park W, Yu JI, et al. Prognostic impact of elective supraclavicular nodal irradiation for patients with N1 breast cancer after lumpectomy and anthracycline plus taxane-based chemotherapy (KROG 1418): a multicenter case-controlled study. Cancer Res Treat 2017;49:970-80. https://doi.org/10.4143/crt.2016.382
  25. Biancosino A, Bremer M, Karstens JH, Biancosino C, Meyer A. Postoperative periclavicular radiotherapy in breast cancer patients with 1-3 positive axillary lymph nodes: outcome and morbidity. Strahlenther Onkol 2012;188:417-23. https://doi.org/10.1007/s00066-012-0083-6
  26. Livi L, Scotti V, Saieva C, et al. Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer: implications for supraclavicular nodal irradiation. Int J Radiat Oncol Biol Phys 2010;76:978-83. https://doi.org/10.1016/j.ijrobp.2009.03.001
  27. Hirata K, Yoshimura M, Inoue M, et al. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. J Radiat Res 2017;58:79-85. https://doi.org/10.1093/jrr/rrw071
  28. Rutgers E, Aalders K, Poncet C, et al. Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: analysis of risk factors including the 70-gene signature. Eur J Cancer 2018;92:S7-S8.
  29. Reddy SG, Kiel KD. Supraclavicular nodal failure in patients with one to three positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, without supraclavicular node radiation. Breast J 2007;13:12-8. https://doi.org/10.1111/j.1524-4741.2006.00357.x
  30. Castaneda CA, Rebaza P, Castillo M, et al. Critical review of axillary recurrence in early breast cancer. Crit Rev Oncol Hematol 2018;129:146-52. https://doi.org/10.1016/j.critrevonc.2018.06.013
  31. Wennberg B, Gagliardi G, Sundbom L, Svane G, Lind P. Early response of lung in breast cancer irradiation: radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol Phys 2002;52:1196-206. https://doi.org/10.1016/S0360-3016(01)02770-5
  32. Chua B, Ung O, Boyages J. Competing considerations in regional nodal treatment for early breast cancer. Breast J 2002;8:15-22. https://doi.org/10.1046/j.1524-4741.2002.08004.x